閉経後骨粗鬆症治療の世界市場レポート 2025年

閉経後骨粗鬆症治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.2％で134億4,000万米ドルに成長します。予測期間の成長は、ヘルスケアインフラの成長、スクリーニングプログラムの増加、精密医療アプローチ、骨粗鬆症治療におけるバイオシミラー、女性の健康プログラムにおける骨の健康、デジタルヘルスの統合、再生医療アプローチに起因すると考えられます。予測期間における主な動向には、診断の進歩、新薬開発、新たな治療法、新薬開発のための共同研究、aiの統合などが含まれます。

骨粗鬆症の有病率の増加が予測され、閉経後骨粗鬆症治療市場の成長を牽引するとみられます。骨粗鬆症は、骨量の減少と骨組織の弱体化を特徴とし、骨折のリスクを高める。閉経後骨粗鬆症治療は、骨粗鬆症の予防や管理、骨折リスクの軽減、全体的な健康増進に重要な役割を果たしています。Healthy Bones Australiaの報告によると、骨粗鬆症または骨減少症に関連する骨折が2021年の178,439件から2022年には183,105件に増加することが明らかになり、閉経後の効果的な骨粗鬆症治療の必要性が強調されています。

肥満の有病率の上昇は、今後の閉経後骨粗鬆症治療市場の成長を牽引すると予想されます。肥満は、健康に悪影響を及ぼす体脂肪の過剰な蓄積によって特徴づけられる病状です。閉経後骨粗鬆症の治療は、骨密度を高め、骨折リスクを低減し、骨を強化し、骨量の減少を遅らせることで全体的な骨の健康を改善することができるため、肥満症の患者にとって特に有益です。このような包括的な健康管理は、運動能力や自立性に大きく影響する骨折のリスクを低下させ、生活の質の向上につながります。例えば、米国を拠点とする非営利団体であるアウトドア産業協会（OIA）は2023年、2022年のアウトドア・レクリエーション参加者が2.3％増加し、過去最高の1億6,810万人に達すると報告しており、これは6歳以上の米国人口の55％を占める。このように、肥満の蔓延が閉経後骨粗鬆症治療市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の閉経後骨粗鬆症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の閉経後骨粗鬆症治療市場：成長率分析
• 世界の閉経後骨粗鬆症治療市場の実績：規模と成長, 2019-2024
• 世界の閉経後骨粗鬆症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の閉経後骨粗鬆症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の閉経後骨粗鬆症治療市場：薬剤タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビスフォスフォネート
• ビタミンD3
• エストロゲン作動薬または拮抗薬
• ホルモン補充療法
• 副甲状腺ホルモン療法
• その他の薬剤タイプ
• 世界の閉経後骨粗鬆症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の閉経後骨粗鬆症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の閉経後骨粗鬆症治療市場、薬剤タイプ別サブセグメンテーション：ビスフォスフォネート、実績と予測, 2019-2024, 2024-2029F, 2034F
• アレンドロネート
• リセドロネート
• ゾレドロン酸
• 世界の閉経後骨粗鬆症治療市場、薬剤タイプ別サブセグメンテーション：ビタミンD3、実績と予測, 2019-2024, 2024-2029F, 2034F
• コレカルシフェロール
• エルゴカルシフェロール
• 世界の閉経後骨粗鬆症治療市場、薬剤タイプ別サブセグメンテーション：エストロゲン作動薬または拮抗薬、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的エストロゲン受容体モジュレーター（SERM）
• タモキシフェン：選択的エストロゲン受容体モジュレーター（SERM）
• タモキシフェン
• 世界の閉経後骨粗鬆症治療市場、薬剤タイプ別サブセグメンテーション：ホルモン補充療法、実績と予測, 2019-2024, 2024-2029F, 2034F
• エストロゲン療法
• エストロゲン・プロゲスチン併用療法
• 世界の閉経後骨粗鬆症治療市場、薬剤タイプ別サブセグメンテーション：副甲状腺ホルモン療法、実績と予測, 2019-2024, 2024-2029F, 2034F
• テリパラチド
• アバロパラチド
• 世界の閉経後骨粗鬆症治療市場、薬剤タイプ別サブセグメンテーション：その他の薬剤タイプ、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルシトニン
• RANKリガンド阻害剤

第7章 地域別・国別分析

• 世界の閉経後骨粗鬆症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の閉経後骨粗鬆症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 閉経後骨粗鬆症治療市場：競合情勢
• 閉経後骨粗鬆症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Novartis AG
• Sanofi SA
• Eli Lilly and Company
• Amgen Inc.
• Asahi Kasei Corporation
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sandoz International GmbH
• Fresenius Kabi AG
• Daiichi Sankyo Company Ltd.
• Sun Pharmaceutical Industries Ltd.
• Cipla Inc.
• Dr.Reddys Laboratories Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 閉経後骨粗鬆症治療市場2029：新たな機会を提供する国
• 閉経後骨粗鬆症治療市場2029：新たな機会を提供するセグメント
• 閉経後骨粗鬆症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Postmenopausal osteoporosis treatment refers to medical interventions and strategies aimed at managing and preventing bone loss and fractures in women after menopause. Postmenopausal osteoporosis is characterized by decreased bone density and an increased susceptibility to fractures due to hormonal changes after menopause.

The main types of drugs used in postmenopausal osteoporosis treatment include bisphosphonates, vitamin D3, estrogen agonists or antagonists, hormone replacement therapy, parathyroid hormone therapy, and others. Bisphosphonates, a class of medications, are commonly used to treat various bone-related conditions, with osteoporosis being a notable example. These medications can be administered through oral, parenteral, and other routes, and they are available through various distribution channels, including hospital pharmacies, retail pharmacies, and others.

The postmenopausal osteoporosis treatment market research report is one of a series of new reports from The Business Research Company that provides postmenopausal osteoporosis treatment market statistics, including postmenopausal osteoporosis treatment industry global market size, regional shares, competitors with a postmenopausal osteoporosis treatment market share, detailed postmenopausal osteoporosis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the postmenopausal osteoporosis treatment industry. This postmenopausal osteoporosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The postmenopausal osteoporosis treatment market size has grown steadily in recent years. It will grow from $10.1 billion in 2024 to $10.58 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to aging population, hormone replacement therapy, increased awareness, fracture risk reduction, nutritional supplements

The postmenopausal osteoporosis treatment market size is expected to see strong growth in the next few years. It will grow to $13.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to healthcare infrastructure growth, increased screening programs, precision medicine approaches, biosimilars in osteoporosis treatment, bone health in women's health programs, digital health integration, regenerative medicine approaches. Major trends in the forecast period include diagnostic advances, new drug development, emerging therapies, collaborations for drug development, integration of ai.

The projected increase in osteoporosis prevalence is expected to drive the growth of the postmenopausal osteoporosis treatment market. Osteoporosis, characterized by reduced bone mass and weakened bone tissue, poses an increased risk of fractures. Postmenopausal osteoporosis treatment plays a crucial role in preventing or managing the condition, reducing fracture risks, and enhancing overall health outcomes. A report from Healthy Bones Australia revealed a rise in fractures related to osteoporosis or osteopenia from 178,439 in 2021 to 183,105 in 2022, emphasizing the need for effective postmenopausal osteoporosis treatments.

The rising prevalence of obesity is expected to drive the growth of the postmenopausal osteoporosis treatment market in the future. Obesity is a medical condition marked by an excessive accumulation of body fat that can negatively affect health. Treatment for postmenopausal osteoporosis is particularly beneficial for individuals with obesity, as it helps increase bone density, reduce fracture risk, strengthen bones, and improve overall bone health by slowing down bone loss. This comprehensive health management can lead to a better quality of life by decreasing the risk of fractures, which significantly impacts mobility and independence. For example, in 2023, the Outdoor Industry Association (OIA), a U.S.-based non-profit, reported a 2.3% increase in outdoor recreation participants in 2022, reaching an all-time high of 168.1 million, which constitutes 55% of the U.S. population aged six and older. Thus, the growing prevalence of obesity is fueling the expansion of the postmenopausal osteoporosis treatment market.

Product innovations are emerging as a significant trend in the postmenopausal osteoporosis treatment market. Major companies in this sector are concentrating on developing innovative products, such as parathyroid hormone, to enhance efficacy and patient adherence. They are also investigating combination therapies and personalized medicine to improve treatment outcomes. Additionally, there is a strong emphasis on long-term safety studies and patient support programs to address concerns and encourage compliance. Parathyroid hormone (PTH) is produced by the parathyroid glands and plays a crucial role in regulating calcium levels in the blood. It promotes calcium release from bones, enhances reabsorption in the kidneys, and activates vitamin D to increase intestinal calcium absorption. For example, in November 2023, Apotex Corp., a pharmaceutical company based in Canada, launched teriparatide, a recombinant parathyroid hormone that significantly boosts bone mineral density and reduces fracture risk in individuals with osteoporosis. Its anabolic effects stimulate bone formation, making it an essential treatment for high-risk patients.

Major companies in the postmenopausal osteoporosis treatment market are striving to gain a competitive edge through innovative products. Advanced bone-building medications, typically administered through injections to promote bone health and density, are a focus of development. In November 2023, Teva Pharmaceuticals Inc., a U.S-based pharmaceutical company, received FDA approval for Forteo (teriparatide injection), catering to postmenopausal women with osteoporosis at high fracture risk. The approval underscores the significance of innovative bone-building medications in treating osteoporosis in both men and women.

Major companies operating in the postmenopausal osteoporosis treatment market include Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Dr.Reddys Laboratories Ltd., Hikma Pharmaceuticals PLC., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Takeda Pharmaceutical Company Limited, Lupin Limited, Ligand Pharmaceuticals Incorporated, Torrent Pharmaceuticals Limited.

North America was the largest region in the postmenopausal osteoporosis treatment market in 2024. The regions covered in the postmenopausal osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the postmenopausal osteoporosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The postmenopausal osteoporosis treatment market consists of revenues earned by entities by providing screening and diagnosis, bone density testing, and risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The postmenopausal osteoporosis treatment market also includes sales of selective estrogen receptor modulators and osteoporosis drugs that are used for the treatment of postmenopausal osteoporosis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Postmenopausal Osteoporosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on postmenopausal osteoporosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for postmenopausal osteoporosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The postmenopausal osteoporosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Bisphosphonates; Vitamin D3; Estrogen Agonist Or Antagonist; Hormone Replacement Therapy; Parathyroid Hormone Therapy; Other Drug Types
• 2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Bisphosphonates: Alendronate; Risedronate; Zoledronic Acid
• 2) By Vitamin D3: Cholecalciferol; Ergocalciferol
• 3) By Estrogen Agonist Or Antagonist: Selective Estrogen Receptor Modulators (SERMs); Tamoxifen
• 4) By Hormone Replacement Therapy: Estrogen Therapy; Combined Estrogen-Progestin Therapy
• 5) By Parathyroid Hormone Therapy: Teriparatide; Abaloparatide
• 6) By Other Drug Types: Calcitonin; RANK Ligand Inhibitors
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; F. Hoffmann-La Roche AG; Merck and Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Postmenopausal Osteoporosis Treatment Market Characteristics

3. Postmenopausal Osteoporosis Treatment Market Trends And Strategies

4. Postmenopausal Osteoporosis Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Postmenopausal Osteoporosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Postmenopausal Osteoporosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Postmenopausal Osteoporosis Treatment Market Growth Rate Analysis
• 5.4. Global Postmenopausal Osteoporosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Postmenopausal Osteoporosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Postmenopausal Osteoporosis Treatment Total Addressable Market (TAM)

6. Postmenopausal Osteoporosis Treatment Market Segmentation

• 6.1. Global Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bisphosphonates
• Vitamin D3
• Estrogen Agonist Or Antagonist
• Hormone Replacement Therapy
• Parathyroid Hormone Therapy
• Other Drug Types
• 6.2. Global Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.3. Global Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.4. Global Postmenopausal Osteoporosis Treatment Market, Sub-Segmentation Of Bisphosphonates, By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alendronate
• Risedronate
• Zoledronic Acid
• 6.5. Global Postmenopausal Osteoporosis Treatment Market, Sub-Segmentation Of Vitamin D3, By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cholecalciferol
• Ergocalciferol
• 6.6. Global Postmenopausal Osteoporosis Treatment Market, Sub-Segmentation Of Estrogen Agonist Or Antagonist, By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Estrogen Receptor Modulators (SERMs)
• Tamoxifen: Selective Estrogen Receptor Modulators (SERMs)
• Tamoxifen
• 6.7. Global Postmenopausal Osteoporosis Treatment Market, Sub-Segmentation Of Hormone Replacement Therapy, By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Therapy
• Combined Estrogen-Progestin Therapy
• 6.8. Global Postmenopausal Osteoporosis Treatment Market, Sub-Segmentation Of Parathyroid Hormone Therapy, By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Teriparatide
• Abaloparatide
• 6.9. Global Postmenopausal Osteoporosis Treatment Market, Sub-Segmentation Of Other Drug Types, BY Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcitonin
• RANK Ligand Inhibitors

7. Postmenopausal Osteoporosis Treatment Market Regional And Country Analysis

• 7.1. Global Postmenopausal Osteoporosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Postmenopausal Osteoporosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Postmenopausal Osteoporosis Treatment Market

• 8.1. Asia-Pacific Postmenopausal Osteoporosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Postmenopausal Osteoporosis Treatment Market

• 9.1. China Postmenopausal Osteoporosis Treatment Market Overview
• 9.2. China Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Postmenopausal Osteoporosis Treatment Market

• 10.1. India Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Postmenopausal Osteoporosis Treatment Market

• 11.1. Japan Postmenopausal Osteoporosis Treatment Market Overview
• 11.2. Japan Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Postmenopausal Osteoporosis Treatment Market

• 12.1. Australia Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Postmenopausal Osteoporosis Treatment Market

• 13.1. Indonesia Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Postmenopausal Osteoporosis Treatment Market

• 14.1. South Korea Postmenopausal Osteoporosis Treatment Market Overview
• 14.2. South Korea Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Postmenopausal Osteoporosis Treatment Market

• 15.1. Western Europe Postmenopausal Osteoporosis Treatment Market Overview
• 15.2. Western Europe Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Postmenopausal Osteoporosis Treatment Market

• 16.1. UK Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Postmenopausal Osteoporosis Treatment Market

• 17.1. Germany Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Postmenopausal Osteoporosis Treatment Market

• 18.1. France Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Postmenopausal Osteoporosis Treatment Market

• 19.1. Italy Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Postmenopausal Osteoporosis Treatment Market

• 20.1. Spain Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Postmenopausal Osteoporosis Treatment Market

• 21.1. Eastern Europe Postmenopausal Osteoporosis Treatment Market Overview
• 21.2. Eastern Europe Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Postmenopausal Osteoporosis Treatment Market

• 22.1. Russia Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Postmenopausal Osteoporosis Treatment Market

• 23.1. North America Postmenopausal Osteoporosis Treatment Market Overview
• 23.2. North America Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Postmenopausal Osteoporosis Treatment Market

• 24.1. USA Postmenopausal Osteoporosis Treatment Market Overview
• 24.2. USA Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Postmenopausal Osteoporosis Treatment Market

• 25.1. Canada Postmenopausal Osteoporosis Treatment Market Overview
• 25.2. Canada Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Postmenopausal Osteoporosis Treatment Market

• 26.1. South America Postmenopausal Osteoporosis Treatment Market Overview
• 26.2. South America Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Postmenopausal Osteoporosis Treatment Market

• 27.1. Brazil Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Postmenopausal Osteoporosis Treatment Market

• 28.1. Middle East Postmenopausal Osteoporosis Treatment Market Overview
• 28.2. Middle East Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Postmenopausal Osteoporosis Treatment Market

• 29.1. Africa Postmenopausal Osteoporosis Treatment Market Overview
• 29.2. Africa Postmenopausal Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Postmenopausal Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Postmenopausal Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Postmenopausal Osteoporosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Postmenopausal Osteoporosis Treatment Market Competitive Landscape
• 30.2. Postmenopausal Osteoporosis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Postmenopausal Osteoporosis Treatment Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi SA
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Asahi Kasei Corporation
• 31.7. Viatris Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Mylan N.V.
• 31.10. Sandoz International GmbH
• 31.11. Fresenius Kabi AG
• 31.12. Daiichi Sankyo Company Ltd.
• 31.13. Sun Pharmaceutical Industries Ltd.
• 31.14. Cipla Inc.
• 31.15. Dr.Reddys Laboratories Ltd.

32. Global Postmenopausal Osteoporosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Postmenopausal Osteoporosis Treatment Market

34. Recent Developments In The Postmenopausal Osteoporosis Treatment Market

35. Postmenopausal Osteoporosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Postmenopausal Osteoporosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Postmenopausal Osteoporosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Postmenopausal Osteoporosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer